CA2661616A1 - Process for preparing pramipexole dihydrochloride tablets - Google Patents
Process for preparing pramipexole dihydrochloride tablets Download PDFInfo
- Publication number
- CA2661616A1 CA2661616A1 CA002661616A CA2661616A CA2661616A1 CA 2661616 A1 CA2661616 A1 CA 2661616A1 CA 002661616 A CA002661616 A CA 002661616A CA 2661616 A CA2661616 A CA 2661616A CA 2661616 A1 CA2661616 A1 CA 2661616A1
- Authority
- CA
- Canada
- Prior art keywords
- pramipexole dihydrochloride
- intra
- tablets
- granular tableting
- granular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Abstract
The present invention relates to a process for preparing tablets of pramipexole dihydrochloride. In particular, the present invention relates to a process for preparing tablets of pramipexole dihydrochloride wherein the tablets exhibit high storage stability properties.
Description
PROCESS FOR PREPARING PRAMiPEXOLE DIHYDROCHLORI.DE
TABLETS
Field of the Invention [00011 The present invention relates to a process for preparing tablets of pramipexole dihydrochloride. In particular, the present invention relates to a process for preparing tablets of pramipexole dihydrochloride wherein the tablets exhibit high storage stability properties.
Background of the Invention [00021 Pramipexole is a known dopamine D2 receptor agonist. It is structurally different from the ergot-derived drugs, e.g., bromocriptine or pergolide. It is also pharmacologically unique in that it is a full agonist and has receptor selectivity for the dopamine D2 family of dopamine receptors.
Pramipexole was originally disclosed in U.S. Patent Nos. 4,731,374, 4,843,086 and 4,886,812, all of which are incorporated herein by reference.
[0003J Pramipexole is designated chemically as (S)-2-amino-4,5,6,7-tetrahydro-(propylamino)benzothiazole and has the molecular formula C,o.Hl7N3S and a relative molecular mass of 211.33. The chemical for.rnula is as follows:
N
i ~-NHz V `N s H
100041 The solvate form commonly used is pramipexole dihydrochloride monohydrate (molecular formula ClaH21C12N30S; relative molecular mass 302.27). Pramipexole dihydrochloride monohydrate is a white to ofF white, tasteless, crystalline powder. Melting occurs in the range of 296 C to 301 C, with decomposition. Pramipexole is a chiral compound with one chiral center.
The pure (S)-enantiomer is obtained from the synthetic process by chiral recrystallization of one of the intermediates during synthesis.
[00051 Pramipexole dihydrochloride monobydrate is a highly soluble compound.
Water solubility is more than 20 mg/mL and :solubility in buffer media is generally above 10 mg/mL between pH 2 and pH 7.4. Pramipexole dffiydrochloride monohydrate is not hygroscopic, and has a highly crystalline nature. Under milling, the crystal modification (monohydrate) does not change.
Pramipexole is very stable in the solid state, yet in solution it is light sensitive.
[0006] Pramipexole immediate release (IR) tablets were first authorized in the USA in 1997, followed over the course of the next few years by marketing authorizations in the European Union (EU), Switzerland, Canada, and South America as well as in countries in Eastern Europe, the Near East, and Asia.
[00071 Pramipexole IR tablets are indicated in the EU and US for the treatment of signs and symptoms of either early Parkinson's Disease or advanced Parkinson's Disease in combination with Levodopa. The product is known in the USA under the brand name MIRAPEX ..
The IR tablets are indicated to be taken 3 times a day.
100081 The manufacturing process for pramipexole dihydrochloride monohydrate tablets, which was marketed in the USA in 2005 (the marketed package/product hereinafter referred to as the "commercial formulation"), results in a tablet which has a relatively stable shelf life wherein approximately 95% of the labeled average amount of the active ingredient remains in the tablet after 18 months of storage. However, it is desirable to develop products having as close to zero degradation as possible upon being stored for extended periods of time.
[0091 The present invention relates to a process for preparing tablets of pramipexole dihydr~ochloride monohydrate wherein the tablets exhibit high storage stability properties.
Summary of the Cnvention [00I0] For purposes of this disclosure and invention, hereinafter the tertn.
"pramipexole dihydrochloride" means pramipexole dffiydrochloride and the pharmaceutically acceptable solvates thereof in particular including the monohydrate of pramipexole dibydrochloride.
[00111 In accordance with the present invention, there is provided a process for producing tablets of pramipexole dihydrochloride wherein the tablets exhibit high .storage stability properties.
{0012[ Furt.her provided is a process for preparing tablets of prarnipexole dihydrochloride wherein the process involves formulating tablets comprising intra-granular tableting ingredients, pramipexole dihydrochloride, a binder and extra-granular tableting agents. The process comprises the steps of optionally sizing the intra-granular tableting ingredients to form substantially uniform sized particles of intra-granular tableting ingredients., forniing a premix comprising the - optionally substantiallyuniform.sized - intra-.granular tableting ingredients, the pramipexole dihydrochloride and the binder, granulating the premix and drying said granulated premix to an endpoint moisture content of from about 1.5% to about 2.5 /a, more preferably 1.0% to about 2.5% to form a dried premix, mixing the extra-granular tableting agents with the dried premix to form a final blend and compressing the final blend into tablets.
[0013] Further provided is a process for preparing pramipexole dihydrochloride tablets comprising intra-granular tableting ingredients, pramipexole dihydrochloride, a binder and extra-granular tableting agents, wherein at least a portion of the process is performed in a closed system and comprises the steps op (a) loading particles of the intra-granular tableting ingredients into a fluid bed granulator wherein the particles of the intra-granular tableting ingredients may optionally be sized prior to loading to form substantially uniform sized particles and mixing the ingredients, (b) dissolving the pramipexole dihydrochloride and povidone in water to form an aqueous pramipexole dihydrochloride solution and spraying the pramipexole dihydrochloride solution onto the particles of intra-granular tableting ingredients in the fluid bed granulator, (c) preparing a binder paste and/or pasty suspension and/or suspension and adding the binder paste and/or pasty suspension and/or suspension to the fluid bed granulator by spraying to form a granulate, (d) drying said granulated mix to an endpoint rnoisture content of from about 1.0% to about 2.5%, (e) optionally pass the dried granulate through a screening mill to the raw granulate (f) mixing said granulated premix of step (e) with the extra-granular tableting agents and blending to form a fmal blend, (g) compressing the final blend into tablets using a tablet .press.
[00141 In a preferred embodiment is provided a process for preparing pramipexole dihydrochloride tablets comprising intra- granular tableting ingredients, pramipexole dffiydrochloride, a binder and extra-granular tableting agents, wherein at least a portion of the process is performed in a closed system and comprises the steps of:
TABLETS
Field of the Invention [00011 The present invention relates to a process for preparing tablets of pramipexole dihydrochloride. In particular, the present invention relates to a process for preparing tablets of pramipexole dihydrochloride wherein the tablets exhibit high storage stability properties.
Background of the Invention [00021 Pramipexole is a known dopamine D2 receptor agonist. It is structurally different from the ergot-derived drugs, e.g., bromocriptine or pergolide. It is also pharmacologically unique in that it is a full agonist and has receptor selectivity for the dopamine D2 family of dopamine receptors.
Pramipexole was originally disclosed in U.S. Patent Nos. 4,731,374, 4,843,086 and 4,886,812, all of which are incorporated herein by reference.
[0003J Pramipexole is designated chemically as (S)-2-amino-4,5,6,7-tetrahydro-(propylamino)benzothiazole and has the molecular formula C,o.Hl7N3S and a relative molecular mass of 211.33. The chemical for.rnula is as follows:
N
i ~-NHz V `N s H
100041 The solvate form commonly used is pramipexole dihydrochloride monohydrate (molecular formula ClaH21C12N30S; relative molecular mass 302.27). Pramipexole dihydrochloride monohydrate is a white to ofF white, tasteless, crystalline powder. Melting occurs in the range of 296 C to 301 C, with decomposition. Pramipexole is a chiral compound with one chiral center.
The pure (S)-enantiomer is obtained from the synthetic process by chiral recrystallization of one of the intermediates during synthesis.
[00051 Pramipexole dihydrochloride monobydrate is a highly soluble compound.
Water solubility is more than 20 mg/mL and :solubility in buffer media is generally above 10 mg/mL between pH 2 and pH 7.4. Pramipexole dffiydrochloride monohydrate is not hygroscopic, and has a highly crystalline nature. Under milling, the crystal modification (monohydrate) does not change.
Pramipexole is very stable in the solid state, yet in solution it is light sensitive.
[0006] Pramipexole immediate release (IR) tablets were first authorized in the USA in 1997, followed over the course of the next few years by marketing authorizations in the European Union (EU), Switzerland, Canada, and South America as well as in countries in Eastern Europe, the Near East, and Asia.
[00071 Pramipexole IR tablets are indicated in the EU and US for the treatment of signs and symptoms of either early Parkinson's Disease or advanced Parkinson's Disease in combination with Levodopa. The product is known in the USA under the brand name MIRAPEX ..
The IR tablets are indicated to be taken 3 times a day.
100081 The manufacturing process for pramipexole dihydrochloride monohydrate tablets, which was marketed in the USA in 2005 (the marketed package/product hereinafter referred to as the "commercial formulation"), results in a tablet which has a relatively stable shelf life wherein approximately 95% of the labeled average amount of the active ingredient remains in the tablet after 18 months of storage. However, it is desirable to develop products having as close to zero degradation as possible upon being stored for extended periods of time.
[0091 The present invention relates to a process for preparing tablets of pramipexole dihydr~ochloride monohydrate wherein the tablets exhibit high storage stability properties.
Summary of the Cnvention [00I0] For purposes of this disclosure and invention, hereinafter the tertn.
"pramipexole dihydrochloride" means pramipexole dffiydrochloride and the pharmaceutically acceptable solvates thereof in particular including the monohydrate of pramipexole dibydrochloride.
[00111 In accordance with the present invention, there is provided a process for producing tablets of pramipexole dihydrochloride wherein the tablets exhibit high .storage stability properties.
{0012[ Furt.her provided is a process for preparing tablets of prarnipexole dihydrochloride wherein the process involves formulating tablets comprising intra-granular tableting ingredients, pramipexole dihydrochloride, a binder and extra-granular tableting agents. The process comprises the steps of optionally sizing the intra-granular tableting ingredients to form substantially uniform sized particles of intra-granular tableting ingredients., forniing a premix comprising the - optionally substantiallyuniform.sized - intra-.granular tableting ingredients, the pramipexole dihydrochloride and the binder, granulating the premix and drying said granulated premix to an endpoint moisture content of from about 1.5% to about 2.5 /a, more preferably 1.0% to about 2.5% to form a dried premix, mixing the extra-granular tableting agents with the dried premix to form a final blend and compressing the final blend into tablets.
[0013] Further provided is a process for preparing pramipexole dihydrochloride tablets comprising intra-granular tableting ingredients, pramipexole dihydrochloride, a binder and extra-granular tableting agents, wherein at least a portion of the process is performed in a closed system and comprises the steps op (a) loading particles of the intra-granular tableting ingredients into a fluid bed granulator wherein the particles of the intra-granular tableting ingredients may optionally be sized prior to loading to form substantially uniform sized particles and mixing the ingredients, (b) dissolving the pramipexole dihydrochloride and povidone in water to form an aqueous pramipexole dihydrochloride solution and spraying the pramipexole dihydrochloride solution onto the particles of intra-granular tableting ingredients in the fluid bed granulator, (c) preparing a binder paste and/or pasty suspension and/or suspension and adding the binder paste and/or pasty suspension and/or suspension to the fluid bed granulator by spraying to form a granulate, (d) drying said granulated mix to an endpoint rnoisture content of from about 1.0% to about 2.5%, (e) optionally pass the dried granulate through a screening mill to the raw granulate (f) mixing said granulated premix of step (e) with the extra-granular tableting agents and blending to form a fmal blend, (g) compressing the final blend into tablets using a tablet .press.
[00141 In a preferred embodiment is provided a process for preparing pramipexole dihydrochloride tablets comprising intra- granular tableting ingredients, pramipexole dffiydrochloride, a binder and extra-granular tableting agents, wherein at least a portion of the process is performed in a closed system and comprises the steps of:
(Step 1) loading mannitol, silica colloidal anhydrous and maize starch into a fluid bed granulator wherein the particles of the intra-granular tableting ingredients may optionally be sized prior to loading to forcn substantially uniform sized particles and mix the ingredients, preferably as a dry mixture, (Step 2) dissolving the pramipexole dihydrochloride in water and povidone to form an aqueous pramipexole dihydrochloride solution and spraying the pramipexole dihydrochloride solution onto the particles of intra-granular tableting ingredients in the fluid bed granulator, (Step 3) preparing.a paste of suspend maize starch in purified water and adding the same to the fluid bed granulator to form a granulate (Fluid Bed Granulation), while preferably protecting the wet granulate from light.
(Step 4) drying the granulate, preferably while protecting the dried granulate from light.
(Step 5) preparing a raw granulate by a screening mill passing through the dried granulate;
(Step 6) blending .the raw granulate with magnesium stearate, silica colloidal anhydrous and maize starch by means of a diffusion mixer (final blend).
(Step 7) pressing the final blend into tablets of the final strengths (Tablets), e.g. about 210 mg.
(Step 8) optionally packaging.
[0015] The tablets produced in accordance with the aforementioned process and embodiments thereof exhibit high storage stability attnbutes.
100161 A further aspect of the invention includes a process for the manufacture of a pharmaceutical tablet formulation comprising pramipexole dihydrochloride, wherein the average amount ofpramipexole dihydrochloride remaining.in the tablet at 18 months under storage conditions of 25 C and a relative humidity of 60% is at least about 97%of the labeled amount.
100171 Another aspect of the invention includes a process for the manufacture a pharmaceutical tablet formulation comprising pramipexole dihydrochloride, wherein the average amount ofpraznipexole dihydrochloride remaining in the tablet at 24 months under storage conditions of 25 C and a relative hum.idity of 60% is at least about 95% of the labeled amount and further may be, preferably, at least about 97%.
100181 Another aspect of the invention includes a process for the manufacture a pharmaceutical tablet formulation comprising pramipexole dihydrochloride, wherein the average amount ofp.ramipexole dihydrocliloride remaining in the tablet at 36 months under storage conditions of 25 C and a relative huniidity of 60% is at least about 95% of the labeled amount and further may be, preferably, at least about 97%.
[0019] The terrn "average amount" as used herein is calculated by determining the amount of the designated product (either active ingredient or degradation product) present in a particular sample of product and then taking an average of the samples of product.
100201 Usually in the final commercial pramipexole product, the tablets are included .as packaged products and packaging may include bottles, blister packs or the like.
[00211 These and other features, benefits and advantages of the invention wilI
be apparent from the following disclosure.
.Brief Description of the Drawings 100221 FIG. 1 is a flow chart showing a process for producing pramipexole dihydrochloride tablets according to one aspect of the invention.
Detailed Description of the Invention [0023] According to the present invention, pramipexole dihydrochloride tablets can be prepared which exhibit high storage stability. This is valuable in the pharmaceutical arena as it enables pharmaceutical manufacturers to produce and store the pramipexole dibydrochloride tablets for long periods thereby reducing concern as to whether the product has exceeded its life and requires disposal. This, in turn, eziables pharmacies, and ultimately consumers, to enjoy the benefits of reduced costs associated with the need to monitor the efficacy of a product and the need to replenish the market supply due to expiration of the product.
100241 In accordance with the invention, it has been found that by controlling certain parameters during the manufacture of pramipexole dihydrochloride tablets, the resulting tablets exhibit high stability. In particular, controlling the particle size ofintra-granulartableting ingredients so that they possess a relative substantial uniformity (optional), preparation and use of a binder suspension, performing the process in a closed system, as well as controlling the moisture content of the product prior to tableting enables the production of a pramipexole dihydrochloride tablet which has highly desirable storage stability enhancements.
[0025] In accordance with the above, the pramipexole dihydrochloride tablets of the invention comprise intra-granular tableting ingredients, pramipexole dihydro chloride, a binder and extra-granular tableting agents. The process of the invention comprises the steps of sizing the intra-granular tableting ingredients to form substantially uniform sized particles of intra-granular tableting ingredients (optional step), forming a mix comprising the optionally uniformly sized intra-granular tableting ingredients, the pramipexole dihydrochloride and the binder, granulating the mix and drying said granulated mix to an endpoint moisture content (Loss on Drying (LOD) at 95 - 105 C, preferably 105 C) of from about 1.0% to about 2.5% to form a dried mix, mixing the extra-granular tableting agents with the dried mix to form a final blend and compressing the final blend into tablets.
In a further embodiment the granulated mix is dried to an end point moisture content of from about 1.5% to about 2.5%.
[0026] A process for formulating the tablets whicb may result in commercial pramipexole products of high stability is set forth in Figure 1. The process shown in Figure 1 involves a process for preparing pramipexole dihydrochloride tablets comprising intra-granular tableting ingredients, pramipexoie dihydrochloride, a binder and extra-granular tableting agents, wherein at least a portion of the process is performed in a closed system. The process comprises the steps of:
(a) loading particles of the intra-granular tableting ingredients into a fluid bed granulator wherein the particles of the intra-granular tableting ingredients may optionally be sized prior to loading to form substantially uniform sized particles, (b) dissolving the pramipexole dihydrochloride and povidone in water to form an aqueous pramipexole dihydrochloride solution and spraying the prainipexole dihydrochloride solution onto the particles of intra-granular tableting ingredients in the fluid bed granulator, (c) preparing a binder paste and/or pasty suspension and/or suspension and adding the binder suspension to the fluid bed granulator by spraying, (d) mixing the particles of intra-granular tableting ingredients, pramipexole dihydrochloride solution and binder solution in the fluid bed granulator to form a mix, (e) granulating said mix to form a granulated mix, (f) drying said granulated mix to an endpoint moisture content of from about 1.0% to about 2.5%, (g) mixing said granulated mix of step (f) with the extra-granular tableting agents and blending to form a final blend, (h) compressing the final blend into tablets using a tablet press.
[0027] The intra-granular tableting ingredients include mannitol-D USP, colloidal silicon dioxide NF, povidone (K25) USP, corn starch NF and purified water USP.
[0028] The mannitol-D used as starting tnaterial .in the process of the present invention preferably is a mixture of the delta crystal modification and the beta crystal modification. Preferably the percentage in weight of the delta crystal modification exceeds the percentage in weight ofthe beta crystal modification. Preferably the percentage ofthe beta crystal modification is not more than 10%, with the remaining 90% being ofthe delta crystal modification. In one embodiment, the beta content is between 1.0 and 10%, preferably 1.5 and 10%, more preferably 2.0 and 10%
and even more preferably 2.5 and 10%
[00291 The extra-granular tableting agents of the present invention include colloidal silicon dioxide NF, corn starch NF and magnesium stearate NF.
100301 With respect to the intra-granular tableting ingredients and extra granular tableting ingredients, the following table represents the preferred amounts oftableting ingredients in each tablet as a percentage of the overall amount used in each batch as well as the amount of API (pramipexole dihydrochloride):
Table 1 Ingredient % per batch Mannitol-D 50-60 Corn Starch 35-45 Colloidal Silicon Dioxide 1-3 Povidone 1-3 Magnesium Stearate 1-3 fAPI **
**The amount of API (pramipexole dihydrochloride) is dependent upon the desired tablet strength.
[00311 Tablet strengths can be from 0.125 mg to 2.5 mg with typical strengths being 0.125 mg, 0.25 mg, 0.50 mg, 0.75 mg, 1 mg, 1.5 mg and 2.0 mg.
[0032] The following table presents various tablet formulations which are representative, though not lirniting, examples of tablet formulations according to the invention:
Table 2 Component mg/tablet API 0.125 0.25 0.5 1.00 1.25 1.5 Mannitol 49.455 61.00 122.0 121.50 162.00 208.5 Corn starch, dried 25.010 30.90 61.8 61.85 82.55 106.0 Corn starch, undried 7.300 9.00 18.0 18.00 24.00 30.8 Colloidal Silicon Dioxide 0.940 1.20 2.4 2.30 3.10 4.0 Povidone (K25) 0.940 1.15 2.3 2.35 3.10 4.0 Magnesium Stearate 1..230 1.50 3.0 3.00 4.00 5.2 Purified Water * * * * * *
Tablet Weight 85.000 105.00 210.00 210.00 280.00 360.00 * For production, the purified water is adapted to the equipment used and does not appear in the final product.
j00331 The advantages to be realized from using the processes ofthe invention to produce the pramipexole dihydrochloride tablets of the invention include high storage stability properties.
Such high storage stability properties include, but are not necessarily limited to, high shelf life.
[00341 The high shelf life of the pramipexole dihydrochloride tablets prepared according to the processes of the present invention is exhibited by the ability of the tablets to retain a high percentage of active ingredient wben stored under certain conditions.
[0035] In particular, the pramipexole dihydrochloride tablets prepared according to the process of the present invention has an average amount of pramipexole dihydrochloride remaining in the tablet at 18 months under storage conditions of 25 C and a relative humidity of 60% of at least about 97% of the labeled amount. The commercial formulation stored under the same conditions average less than 95.8% of the labeled amount (average amount). The trend for the amount ofactive ingredient present in the stored tablets prepared according to the invention can be projected out to 24 and even 36 months where even at 36 months greater than 95 % of the labeled amount should remain.
This of course is significant as it allows for long shelf life of the product and thus cost savings to consumers as the product does not have to be replaced by the manufacturer too frequently due to expiration of the unused product stored by the manufacturer, distributor and/or pharmacist.
[00361 The following Example is representative of the process used to prepare pram.ipexole dehydrate tablets according to the invention.
Example 2 [0037] The following process was used to prepare 0.5 mg tablets of pramipexole dihydrochloride:
[0038] Into a fluid bed granulator, the following intra-granular ingredients were dispensed while passing through a comil (Quadro) having a 1.4 mm screen:
Mannitol-D: 122,000 g Colloidal Silicon Dioxide: 1,200 g Corn Starch, dried (undried): 56,000 (58,8) g 100391 In a separate stainless steel container, 500 g of .prazn.ipexole dihydrochloride monohydrate was dissolved in 20,000 ml of purified water with stirring and then 2,300 g of polyvidone 25 (Povidone K25 ) was added and dissolved to completion with stirring. The pramipexole dihydrochloride solution was then sprayed onto the mixture of intra-granular ingredients in the fluid bed granulator. In a separate stainless steel container, 5,800 g of dried corn starch (undried 6.09 g) was added to 15,000 ml of purified water with stirring forming a starch paste. The starch paste was then added to 38,000 ml of purified water which had been heated to 95 C and stirred at a rate of from about 350 RPM (stirring can be from about 250 RPM to about 1250 RPM).
An additional 21,000 ml of purified water (room temperature) was then added and stirred at 350 RPM. The temperature was allowed to cool to about 60 C (the temperature can be from about 55 C to about 65 C at this stage). The starch solution was then sprayed onto the intra-granular ingredients and pramipexole dihydrochloride mixture in the fluid bed granulator. The material in the fluid bed granulator was then granulated and dried .to a residual moisture content of 2.3% and sieved through a screening mill to form a pramipexole raw granulate. An extra-granular blend of magnesium stearate (3,000 g), colloidal silicon dioxide (1,200 g) and corn starch (18,000 g) was mixed with 187,800 g of the pramipexole raw granulate in a diffusion mixer for 30 minutes at 10 RPM to form a final blend. The final blend was then compressed into tablets weighing 210 mg and containing 0.5 mg pramipexole dihydrochloride.
[0040] The present invention is not to be linaited in scope by the specific embodiments described herein, which are intended as single illustrations ofip.dividual aspects of the invention, and functionally equivalent methods and components are within the scope of the invention. Indeed, various modifications of the invention, in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.
(Step 4) drying the granulate, preferably while protecting the dried granulate from light.
(Step 5) preparing a raw granulate by a screening mill passing through the dried granulate;
(Step 6) blending .the raw granulate with magnesium stearate, silica colloidal anhydrous and maize starch by means of a diffusion mixer (final blend).
(Step 7) pressing the final blend into tablets of the final strengths (Tablets), e.g. about 210 mg.
(Step 8) optionally packaging.
[0015] The tablets produced in accordance with the aforementioned process and embodiments thereof exhibit high storage stability attnbutes.
100161 A further aspect of the invention includes a process for the manufacture of a pharmaceutical tablet formulation comprising pramipexole dihydrochloride, wherein the average amount ofpramipexole dihydrochloride remaining.in the tablet at 18 months under storage conditions of 25 C and a relative humidity of 60% is at least about 97%of the labeled amount.
100171 Another aspect of the invention includes a process for the manufacture a pharmaceutical tablet formulation comprising pramipexole dihydrochloride, wherein the average amount ofpraznipexole dihydrochloride remaining in the tablet at 24 months under storage conditions of 25 C and a relative hum.idity of 60% is at least about 95% of the labeled amount and further may be, preferably, at least about 97%.
100181 Another aspect of the invention includes a process for the manufacture a pharmaceutical tablet formulation comprising pramipexole dihydrochloride, wherein the average amount ofp.ramipexole dihydrocliloride remaining in the tablet at 36 months under storage conditions of 25 C and a relative huniidity of 60% is at least about 95% of the labeled amount and further may be, preferably, at least about 97%.
[0019] The terrn "average amount" as used herein is calculated by determining the amount of the designated product (either active ingredient or degradation product) present in a particular sample of product and then taking an average of the samples of product.
100201 Usually in the final commercial pramipexole product, the tablets are included .as packaged products and packaging may include bottles, blister packs or the like.
[00211 These and other features, benefits and advantages of the invention wilI
be apparent from the following disclosure.
.Brief Description of the Drawings 100221 FIG. 1 is a flow chart showing a process for producing pramipexole dihydrochloride tablets according to one aspect of the invention.
Detailed Description of the Invention [0023] According to the present invention, pramipexole dihydrochloride tablets can be prepared which exhibit high storage stability. This is valuable in the pharmaceutical arena as it enables pharmaceutical manufacturers to produce and store the pramipexole dibydrochloride tablets for long periods thereby reducing concern as to whether the product has exceeded its life and requires disposal. This, in turn, eziables pharmacies, and ultimately consumers, to enjoy the benefits of reduced costs associated with the need to monitor the efficacy of a product and the need to replenish the market supply due to expiration of the product.
100241 In accordance with the invention, it has been found that by controlling certain parameters during the manufacture of pramipexole dihydrochloride tablets, the resulting tablets exhibit high stability. In particular, controlling the particle size ofintra-granulartableting ingredients so that they possess a relative substantial uniformity (optional), preparation and use of a binder suspension, performing the process in a closed system, as well as controlling the moisture content of the product prior to tableting enables the production of a pramipexole dihydrochloride tablet which has highly desirable storage stability enhancements.
[0025] In accordance with the above, the pramipexole dihydrochloride tablets of the invention comprise intra-granular tableting ingredients, pramipexole dihydro chloride, a binder and extra-granular tableting agents. The process of the invention comprises the steps of sizing the intra-granular tableting ingredients to form substantially uniform sized particles of intra-granular tableting ingredients (optional step), forming a mix comprising the optionally uniformly sized intra-granular tableting ingredients, the pramipexole dihydrochloride and the binder, granulating the mix and drying said granulated mix to an endpoint moisture content (Loss on Drying (LOD) at 95 - 105 C, preferably 105 C) of from about 1.0% to about 2.5% to form a dried mix, mixing the extra-granular tableting agents with the dried mix to form a final blend and compressing the final blend into tablets.
In a further embodiment the granulated mix is dried to an end point moisture content of from about 1.5% to about 2.5%.
[0026] A process for formulating the tablets whicb may result in commercial pramipexole products of high stability is set forth in Figure 1. The process shown in Figure 1 involves a process for preparing pramipexole dihydrochloride tablets comprising intra-granular tableting ingredients, pramipexoie dihydrochloride, a binder and extra-granular tableting agents, wherein at least a portion of the process is performed in a closed system. The process comprises the steps of:
(a) loading particles of the intra-granular tableting ingredients into a fluid bed granulator wherein the particles of the intra-granular tableting ingredients may optionally be sized prior to loading to form substantially uniform sized particles, (b) dissolving the pramipexole dihydrochloride and povidone in water to form an aqueous pramipexole dihydrochloride solution and spraying the prainipexole dihydrochloride solution onto the particles of intra-granular tableting ingredients in the fluid bed granulator, (c) preparing a binder paste and/or pasty suspension and/or suspension and adding the binder suspension to the fluid bed granulator by spraying, (d) mixing the particles of intra-granular tableting ingredients, pramipexole dihydrochloride solution and binder solution in the fluid bed granulator to form a mix, (e) granulating said mix to form a granulated mix, (f) drying said granulated mix to an endpoint moisture content of from about 1.0% to about 2.5%, (g) mixing said granulated mix of step (f) with the extra-granular tableting agents and blending to form a final blend, (h) compressing the final blend into tablets using a tablet press.
[0027] The intra-granular tableting ingredients include mannitol-D USP, colloidal silicon dioxide NF, povidone (K25) USP, corn starch NF and purified water USP.
[0028] The mannitol-D used as starting tnaterial .in the process of the present invention preferably is a mixture of the delta crystal modification and the beta crystal modification. Preferably the percentage in weight of the delta crystal modification exceeds the percentage in weight ofthe beta crystal modification. Preferably the percentage ofthe beta crystal modification is not more than 10%, with the remaining 90% being ofthe delta crystal modification. In one embodiment, the beta content is between 1.0 and 10%, preferably 1.5 and 10%, more preferably 2.0 and 10%
and even more preferably 2.5 and 10%
[00291 The extra-granular tableting agents of the present invention include colloidal silicon dioxide NF, corn starch NF and magnesium stearate NF.
100301 With respect to the intra-granular tableting ingredients and extra granular tableting ingredients, the following table represents the preferred amounts oftableting ingredients in each tablet as a percentage of the overall amount used in each batch as well as the amount of API (pramipexole dihydrochloride):
Table 1 Ingredient % per batch Mannitol-D 50-60 Corn Starch 35-45 Colloidal Silicon Dioxide 1-3 Povidone 1-3 Magnesium Stearate 1-3 fAPI **
**The amount of API (pramipexole dihydrochloride) is dependent upon the desired tablet strength.
[00311 Tablet strengths can be from 0.125 mg to 2.5 mg with typical strengths being 0.125 mg, 0.25 mg, 0.50 mg, 0.75 mg, 1 mg, 1.5 mg and 2.0 mg.
[0032] The following table presents various tablet formulations which are representative, though not lirniting, examples of tablet formulations according to the invention:
Table 2 Component mg/tablet API 0.125 0.25 0.5 1.00 1.25 1.5 Mannitol 49.455 61.00 122.0 121.50 162.00 208.5 Corn starch, dried 25.010 30.90 61.8 61.85 82.55 106.0 Corn starch, undried 7.300 9.00 18.0 18.00 24.00 30.8 Colloidal Silicon Dioxide 0.940 1.20 2.4 2.30 3.10 4.0 Povidone (K25) 0.940 1.15 2.3 2.35 3.10 4.0 Magnesium Stearate 1..230 1.50 3.0 3.00 4.00 5.2 Purified Water * * * * * *
Tablet Weight 85.000 105.00 210.00 210.00 280.00 360.00 * For production, the purified water is adapted to the equipment used and does not appear in the final product.
j00331 The advantages to be realized from using the processes ofthe invention to produce the pramipexole dihydrochloride tablets of the invention include high storage stability properties.
Such high storage stability properties include, but are not necessarily limited to, high shelf life.
[00341 The high shelf life of the pramipexole dihydrochloride tablets prepared according to the processes of the present invention is exhibited by the ability of the tablets to retain a high percentage of active ingredient wben stored under certain conditions.
[0035] In particular, the pramipexole dihydrochloride tablets prepared according to the process of the present invention has an average amount of pramipexole dihydrochloride remaining in the tablet at 18 months under storage conditions of 25 C and a relative humidity of 60% of at least about 97% of the labeled amount. The commercial formulation stored under the same conditions average less than 95.8% of the labeled amount (average amount). The trend for the amount ofactive ingredient present in the stored tablets prepared according to the invention can be projected out to 24 and even 36 months where even at 36 months greater than 95 % of the labeled amount should remain.
This of course is significant as it allows for long shelf life of the product and thus cost savings to consumers as the product does not have to be replaced by the manufacturer too frequently due to expiration of the unused product stored by the manufacturer, distributor and/or pharmacist.
[00361 The following Example is representative of the process used to prepare pram.ipexole dehydrate tablets according to the invention.
Example 2 [0037] The following process was used to prepare 0.5 mg tablets of pramipexole dihydrochloride:
[0038] Into a fluid bed granulator, the following intra-granular ingredients were dispensed while passing through a comil (Quadro) having a 1.4 mm screen:
Mannitol-D: 122,000 g Colloidal Silicon Dioxide: 1,200 g Corn Starch, dried (undried): 56,000 (58,8) g 100391 In a separate stainless steel container, 500 g of .prazn.ipexole dihydrochloride monohydrate was dissolved in 20,000 ml of purified water with stirring and then 2,300 g of polyvidone 25 (Povidone K25 ) was added and dissolved to completion with stirring. The pramipexole dihydrochloride solution was then sprayed onto the mixture of intra-granular ingredients in the fluid bed granulator. In a separate stainless steel container, 5,800 g of dried corn starch (undried 6.09 g) was added to 15,000 ml of purified water with stirring forming a starch paste. The starch paste was then added to 38,000 ml of purified water which had been heated to 95 C and stirred at a rate of from about 350 RPM (stirring can be from about 250 RPM to about 1250 RPM).
An additional 21,000 ml of purified water (room temperature) was then added and stirred at 350 RPM. The temperature was allowed to cool to about 60 C (the temperature can be from about 55 C to about 65 C at this stage). The starch solution was then sprayed onto the intra-granular ingredients and pramipexole dihydrochloride mixture in the fluid bed granulator. The material in the fluid bed granulator was then granulated and dried .to a residual moisture content of 2.3% and sieved through a screening mill to form a pramipexole raw granulate. An extra-granular blend of magnesium stearate (3,000 g), colloidal silicon dioxide (1,200 g) and corn starch (18,000 g) was mixed with 187,800 g of the pramipexole raw granulate in a diffusion mixer for 30 minutes at 10 RPM to form a final blend. The final blend was then compressed into tablets weighing 210 mg and containing 0.5 mg pramipexole dihydrochloride.
[0040] The present invention is not to be linaited in scope by the specific embodiments described herein, which are intended as single illustrations ofip.dividual aspects of the invention, and functionally equivalent methods and components are within the scope of the invention. Indeed, various modifications of the invention, in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.
Claims (7)
1. A process for preparing pramipexole dihydrochloride tablets comprising intra-granular tableting ingredients, pramipexole dihydrochloride or a pharmaceutically acceptable solvate thereof, a binder and extra-granular tableting agents, wherein the process is performed in a closed system and comprises the steps of:
(a) loading particles of the intra-granular tableting ingredients into a fluid bed granulator, (b) dissolving the pramipexole dihydrochloride or pharmaceutically acceptable solvate thereof and povidone in water to form an aqueous pramipexole dihydrochloride solution and spraying the pramipexole dihydrochloride solution to the particles of intra-granular tableting ingredients in the fluid bed granulator, (c) preparing a binder solution, suspension or paste and adding the binder solution, suspension or paste to the fluid bed granulator to form a granulate, (d) drying said granulated premix to an endpoint moisture content of from about 1.0% to about 2.5%, (e) mixing said granulated mix of step with the extra-granular tableting agents and blending to form a final blend, (f) compressing the final blend into tablets using a tablet press.
(a) loading particles of the intra-granular tableting ingredients into a fluid bed granulator, (b) dissolving the pramipexole dihydrochloride or pharmaceutically acceptable solvate thereof and povidone in water to form an aqueous pramipexole dihydrochloride solution and spraying the pramipexole dihydrochloride solution to the particles of intra-granular tableting ingredients in the fluid bed granulator, (c) preparing a binder solution, suspension or paste and adding the binder solution, suspension or paste to the fluid bed granulator to form a granulate, (d) drying said granulated premix to an endpoint moisture content of from about 1.0% to about 2.5%, (e) mixing said granulated mix of step with the extra-granular tableting agents and blending to form a final blend, (f) compressing the final blend into tablets using a tablet press.
2. The process of claim 1 further comprising the step of sizing the intra-granular tableting agents prior to loading to a substantially uniform size.
3. The process of claim 1 wherein pramipexole dihydrochloride monohydrate solvate is used.
4. The process of claim 1 wherein the binder solution is an aqueous suspension or paste comprising corn starch.
5. The process of claim 1 wherein the intra-granular tableting ingredients comprise mannitol-D, colloidal silicone dioxide, and corn starch.
6. The process of claim 1 wherein the extra-granular tableting agents comprise colloidal silicon dioxide, starch and magnesium stearate.
7. The process of claim 5 wherein the mannitol-D has no more than 10% beta modification product present.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46705006A | 2006-08-24 | 2006-08-24 | |
| US11/467,050 | 2006-08-24 | ||
| US11/734,041 | 2007-04-11 | ||
| US11/734,041 US20080254118A1 (en) | 2007-04-11 | 2007-04-11 | Process for preparing pramipexole dihydrochloride tablets |
| PCT/EP2007/058696 WO2008023027A2 (en) | 2006-08-24 | 2007-08-22 | Process for preparing pramipexole dihydrochloride tablets with high storage stability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2661616A1 true CA2661616A1 (en) | 2008-02-28 |
Family
ID=38963081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002661616A Abandoned CA2661616A1 (en) | 2006-08-24 | 2007-08-22 | Process for preparing pramipexole dihydrochloride tablets |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP2056795A2 (en) |
| JP (1) | JP2010501525A (en) |
| KR (1) | KR20090045943A (en) |
| AR (1) | AR062509A1 (en) |
| AU (1) | AU2007287560A1 (en) |
| BR (1) | BRPI0715835A2 (en) |
| CA (1) | CA2661616A1 (en) |
| CL (1) | CL2007002477A1 (en) |
| IL (1) | IL197130A0 (en) |
| MX (1) | MX2009001884A (en) |
| RU (1) | RU2009110253A (en) |
| TW (1) | TW200816998A (en) |
| WO (1) | WO2008023027A2 (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8518926B2 (en) | 2006-04-10 | 2013-08-27 | Knopp Neurosciences, Inc. | Compositions and methods of using (R)-pramipexole |
| JP2009537565A (en) | 2006-05-16 | 2009-10-29 | ノップ ニューロサイエンシーズ、インク． | R (+) and S (-) pramipexole compositions and methods of using the same |
| US8524695B2 (en) | 2006-12-14 | 2013-09-03 | Knopp Neurosciences, Inc. | Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same |
| AU2008224844B2 (en) | 2007-03-14 | 2012-08-09 | Knopp Neurosciences, Inc. | Synthesis of chirally purified substituted benzothiazole diamines |
| US20080254117A1 (en) * | 2007-04-10 | 2008-10-16 | Noel Cotton | Process for preparing pramipexole dihydrochloride tablets |
| EP2334185A4 (en) | 2008-08-19 | 2011-09-21 | Knopp Neurosciences Inc | Compositions and methods of using (r)-pramipexole |
| TR200906997A1 (en) | 2009-09-11 | 2011-03-21 | Sanovel �La� San. Ve T�C. A. �. | Pramipexole pharmaceutical compositions. |
| EP2462925A1 (en) | 2010-11-12 | 2012-06-13 | Neuraxpharm Arzneimittel GmbH | Pramipexole Dihydrochloride Granulate |
| KR101712049B1 (en) * | 2010-11-17 | 2017-03-03 | 엘지이노텍 주식회사 | Light emitting device |
| WO2013096816A1 (en) | 2011-12-22 | 2013-06-27 | Biogen Idec Ma Inc. | Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
| US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
| US9468630B2 (en) | 2013-07-12 | 2016-10-18 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
| PL3019167T3 (en) | 2013-07-12 | 2021-06-14 | Knopp Biosciences Llc | Treating elevated levels of eosinophils and/or basophils |
| ES2871556T3 (en) | 2013-08-13 | 2021-10-29 | Knopp Biosciences Llc | Compositions and methods for the treatment of chronic urticaria |
| US9642840B2 (en) | 2013-08-13 | 2017-05-09 | Knopp Biosciences, Llc | Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0998933A1 (en) * | 1998-10-09 | 2000-05-10 | Boehringer Mannheim Gmbh | Process for producing pharmaceutical compositions containing diphosphonates for oral administration |
| WO2000044353A1 (en) * | 1999-01-29 | 2000-08-03 | Losan Pharma Gmbh | Pharmaceutical compositions |
| US20030133982A1 (en) * | 2001-12-20 | 2003-07-17 | Heimlich John M. | Zero-order sustained release dosage forms and method of making same |
| EP1620075B1 (en) * | 2003-05-07 | 2020-06-24 | Samyang Biopharmaceuticals Corporation | Highly plastic granules for making fast melting tablets |
| NZ553645A (en) * | 2004-08-13 | 2010-09-30 | Boehringer Ingelheim Int | Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
| NZ553561A (en) * | 2004-08-13 | 2010-12-24 | Boehringer Ingelheim Int | Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
| JP4446177B2 (en) * | 2005-01-21 | 2010-04-07 | 東和薬品株式会社 | Method for producing moisture-resistant orally disintegrating tablets |
| JP2009519970A (en) * | 2005-12-15 | 2009-05-21 | アキュスフィア， インコーポレイテッド | Process for producing particle-based pharmaceutical dosage forms for oral administration |
-
2007
- 2007-08-22 CA CA002661616A patent/CA2661616A1/en not_active Abandoned
- 2007-08-22 AU AU2007287560A patent/AU2007287560A1/en not_active Abandoned
- 2007-08-22 BR BRPI0715835-1A patent/BRPI0715835A2/en not_active IP Right Cessation
- 2007-08-22 WO PCT/EP2007/058696 patent/WO2008023027A2/en active Application Filing
- 2007-08-22 RU RU2009110253/15A patent/RU2009110253A/en not_active Application Discontinuation
- 2007-08-22 MX MX2009001884A patent/MX2009001884A/en not_active Application Discontinuation
- 2007-08-22 KR KR1020097006052A patent/KR20090045943A/en not_active Application Discontinuation
- 2007-08-22 JP JP2009525064A patent/JP2010501525A/en active Pending
- 2007-08-22 EP EP07788511A patent/EP2056795A2/en not_active Withdrawn
- 2007-08-23 TW TW096131278A patent/TW200816998A/en unknown
- 2007-08-23 CL CL200702477A patent/CL2007002477A1/en unknown
- 2007-08-24 AR ARP070103757A patent/AR062509A1/en unknown
-
2009
- 2009-02-19 IL IL197130A patent/IL197130A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008023027A2 (en) | 2008-02-28 |
| BRPI0715835A2 (en) | 2013-07-23 |
| TW200816998A (en) | 2008-04-16 |
| WO2008023027A3 (en) | 2008-04-17 |
| CL2007002477A1 (en) | 2008-04-18 |
| EP2056795A2 (en) | 2009-05-13 |
| RU2009110253A (en) | 2010-09-27 |
| AU2007287560A1 (en) | 2008-02-28 |
| JP2010501525A (en) | 2010-01-21 |
| KR20090045943A (en) | 2009-05-08 |
| AR062509A1 (en) | 2008-11-12 |
| IL197130A0 (en) | 2009-11-18 |
| MX2009001884A (en) | 2009-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2661616A1 (en) | Process for preparing pramipexole dihydrochloride tablets | |
| JP7194153B2 (en) | New formulation | |
| JP4084309B2 (en) | Solid formulation containing a single crystal form | |
| AU2009292615B2 (en) | Granulates, process for preparing them and pharmaceutical products containing them | |
| JP5714600B2 (en) | Co-processed tablet excipient mixture, its preparation and use | |
| KR20100121483A (en) | Tablet having improved elution properties | |
| US20130221561A1 (en) | Process for Preparing Pramipexole Dihydrochloride Tablets | |
| NZ555395A (en) | Formulations of substituted benzoxazoles | |
| AU2016203463A1 (en) | Pharmaceutical formulation having improved stability | |
| US20100267960A1 (en) | Process for preparing pramipexole dihydrochloride tablets | |
| RU2106145C1 (en) | Pharmaceutical composition and method for its obtaining (variants) | |
| CN101505734A (en) | Process for preparing pramipexole dihydrochloride tablets with high storage stability | |
| AU2014359499A1 (en) | Pharmaceutical composition | |
| CA2603316C (en) | Combined-step process for pharmaceutical compositions | |
| NZ547880A (en) | Solid pharmaceutical preparation form | |
| EP2227224A2 (en) | Improved pharmaceutical composition containing non-ergoline dopamine agonist and method for the preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |